223 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28613895	66	A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.	Eli Lilly
28274635	381	Identification of novel TACE inhibitors compatible with topical application.	Nestl�
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26641525	6	Azaphilones from an Acid Mine Extremophile Strain of a Pleurostomophora sp.	Memorial Sloan-Kettering Cancer Center
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University Of Minnesota
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25686153	73	Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.	University Of Navarra
25553540	6	1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold.	University Of Mississippi
25725607	15	2-Benzisothiazolylimino-5-benzylidene-4-thiazolidinones as protective agents against cartilage destruction.	University Of Catania
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
23453070	42	A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.	Asahi Kasei Pharma
23353736	41	Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).	Second Military Medical University
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute Of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
11689071	40	Three-dimensional quantitative structure-activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: applying a"divide and conquer" strategy.	University Of Missouri St. Louis
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22658537	76	Natural products as a gold mine for selective matrix metalloproteinases inhibitors.	East China University Of Science And Technology
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
22342144	72	Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.	Panthera Biopharma
19942433	8	A single step purification for autolytic zinc proteinases.	Duke University
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University Of Florida
19635666	119	Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.	Incyte
17981034	51	1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.	Johnson & Johnson Pharmaceutical Research And Development
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
17980583	46	Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).	Johnson & Johnson Pharmaceutical Research And Development
18095654	1	Noreupenifeldin, a tropolone from an unidentified ascomycete.	Merck Research Laboratories
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University Of Jerusalem
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research And Development
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15214773	76	Fragment-based drug discovery.	Sunesis Pharmaceuticals
15139760	110	Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.	The Hebrew University Of Jerusalem
12930146	170	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Institut De Recherches Servier
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11831904	172	New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.	Nippon Organon K.K.
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University Of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter And Gamble Pharmaceuticals
9733482	31	Discovery of potent, achiral matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
12824028	75	Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.	Pfizer
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter And Gamble Pharmaceuticals
11378378	34	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Celltech-Chiroscience
10340614	20	Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
10450979	4	Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.	University Of Cambridge
10397503	40	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Universit£
	5	Solid-phase synthesis of a N-carboxyalkyl tripeptide combinatorial library	TBA
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
22088955	33	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.	Universit£
21925881	60	Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.	Johnson & Johnson Pharmaceutical Research & Development
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University Of Illinois At Chicago
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University Of Notre Dame
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
21078557	34	Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.	Yonsei University
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
	39	Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety	TBA
	97	Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket	TBA
	30	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics	TBA
	17	Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)	TBA
	10	Potent carboxylate inhibitors of stromelysin containing P2′ piperazic acids and P1′ biaryl moeities	TBA
	30	Orally active inhibitors of stromelysin-1 (MMP-3)	TBA
	16	Potent matrix metalloproteinase inhibitors: Amino-carboxylate compounds containing modifications of the P1 residue	TBA
	60	Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptides	TBA
	49	Phosphinic acid inhibitors of matrix metalloproteinases	TBA
	36	Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostere	TBA
	18	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'	TBA
	47	Hydroxamate inhibitors of human gelatinase B (92 kDa)	TBA
	39	Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modifications	TBA
	6	Probing the P3′ pocket of stromelysin with piperazic acid analogs	TBA
	66	Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalanines	TBA
	5	Inhibition of metalloproteinase by futoenone derivatives	TBA
	40	Novel indolactam-based inhibitors of matrix metalloproteinases	TBA
	60	Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivatives	TBA
	76	Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivatives	TBA
	26	Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acids	TBA
19457660	90	Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.	Incyte
19261472	16	Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.	University Of California
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University Of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
18330993	4	The berkeleyamides, amides from the acid lake fungus Penicillum rubrum.	Montana Tech Of The University Of Montana
17848581	13	Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.	Wyeth Research
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18083558	112	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.	Johnson & Johnson Pharmaceutical Research And Development
18068976	132	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.	Incyte
18036818	157	Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.	Incyte
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17583333	4	Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.	Università
17576061	132	Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17267227	12	Synthesis and in vitro evaluation of targeted tetracycline derivatives: effects on inhibition of matrix metalloproteinases.	Clermont Auvergne University
17256836	84	Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.	Incyte
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16632358	68	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.	Johnson & Johnson Pharmaceutical Research And Development
16516469	39	A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.	Novartis Institutes For Biomedical Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16242329	12	N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.	Università
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15780605	2	QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.	Aventis Pharma Deutschland
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
15163188	12	A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.	University Of California San Francisco
15125955	84	Reverse hydroxamate-based selective TACE inhibitors.	Kaken Pharmaceutical
15055993	30	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.	Hokkaido Collaboration Center N-21
15006405	20	Synthesis and biological activity of selective azasugar-based TACE inhibitors.	Organon K.K.
14611841	10	MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.	Umr/Cnrs 6013
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12873505	20	Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12873504	36	Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School Of Medicine
12781187	15	Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Organon K.K.
12477346	30	NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.	Abbott Laboratories
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11844676	48	Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.	Organon K.K.
11831905	33	New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.	Organon K.K.
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11708926	84	Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Glaxosmithkline
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11551755	18	Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.	British Biotech Pharmaceuticals
11543676	45	Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.	Université
11543675	104	N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.	Université
11514157	48	N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.	Glaxosmithkline
11454461	111	The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.	Procter And Gamble Pharmaceuticals
11428927	117	A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.	The Royal Danish School Of Pharmacy
11412980	48	Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.	Abbott Laboratories
11412979	67	Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.	Abbott Laboratories
11354379	37	Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.	Pfizer
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
11297453	173	Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.	Procter And Gamble Pharmaceuticals
11266157	12	Chemoenzymatic synthesis of functionalized cyclohexylglycines and alpha-methylcyclohexylglycines via Kazmaier-Claisen rearrangement.	University Of Florida
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11229773	73	Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.	Pfizer
11212095	65	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Institut De Recherches Servier
11150165	228	Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.	Procter And Gamble Pharmaceuticals
10937713	186	Solid-phase synthesis of an arylsulfone hydroxamate library.	Rhone-Poulenc Rorer
10882354	19	Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.	Pfizer
10669564	189	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.	Procter And Gamble Pharmaceuticals
10639284	119	Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.	University Of Florida
10579815	168	Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.	Hoechst Marion Roussel
10560745	46	Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.	Smithkline Beecham Pharmaceuticals
10522712	109	The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.	British Biotech Pharmaceuticals
10360755	17	P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.	Dupont Pharmaceuticals
10230616	30	Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.	Searle Discovery Research
10229623	82	Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.	Pharmacia And Upjohn
10052961	24	Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.	RhôNe-Poulenc Rorer
10021913	42	Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.	Pfizer
9873712	109	Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.	Abbott Laboratories
9873491	56	The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.	Abbott Laboratories
9873489	28	Design and synthesis of conformationally-constrained MMP inhibitors.	Procter And Gamble Pharmaceuticals
9873367	39	Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.	Abbott Laboratories
9871728	27	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
9871727	58	Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.	Affymax Research Institute
9871551	48	Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.	Dupont Pharmaceuticals
9632351	36	Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.	Affymax Research Institute
9599226	25	Macrocyclic amino carboxylates as selective MMP-8 inhibitors.	Dupont Pharmaceuticals
9599225	9	Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
9548812	67	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Kanebo
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
9191969	31	Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.	Institut De Recherche Servier
9083493	95	Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.	Merck Research Laboratories
8289198	53	A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors.	Warner-Lambert
8277511	57	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.	Merck Research Laboratories
8126708	113	Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.	Glaxo Inc. Research Institute
7629797	73	Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.	Sterling Winthrop Pharmaceuticals Research Division
28558971	38	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.	Merck
28653849	67	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.	Scripps Florida
22299577	12	Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.	Universit?? Di Firenze
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
9463476	21	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.	Suntory Institute For Bioorganic Research
7651361	32	Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.	Georgetown University
7518496	9	Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.	Syntex Discovery Research
19695884	156	Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.	Vernalis (R&D)
19462975	18	Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.	Chemical Genomics Centre Of The Max Planck Society